Colistimethate sodium dry powder inhalation - AbbVie
Alternative Names: Colistimethate sodium inhalation powder - Forest; ColobreatheLatest Information Update: 06 Dec 2023
Price :
$50 *
At a glance
- Originator Forest Laboratories
- Developer AbbVie
- Class Antibacterials; Polymixins
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 11 Feb 2020 moksha8 Pharmaceuticals is now called m8 Pharmaceuticals